Age-Defying Stem-Cell Infusions—Joshua Hare, MD—Longeveron
Finding Genius Podcast
Richard Jacobs
4.4 • 1K Ratings
🗓️ 9 November 2018
⏱️ 23 minutes
🧾️ Download transcript
Summary
Ageing: it's an inevitable part of life, it affects us all, and there's just no way around it. Or is there? "Ageing is a major societal problem that we're turning our attention to in the biotechnology industry as something that's treatable...and that we can modify biologically to improve the health span of people in our country and worldwide," says Dr. Joshua Hare, co-founder, and chief science officer at Longeveron. Founded four years ago after receiving a technology license from the University of Miami Interdisciplinary Stem Cell Institute, Longeveron is a biotech company bringing over 20 years of clinical research and 40 years of basic research to address the problem of ageing.
The team at Longeveron proposes that allogeneic mesenchymal stem cells can be used to treat ageing frailty, a condition that affects 50 percent of people over the age of 65. Dr. Hare discusses the evidence in support of his hypothesis, the regenerative and reparative potential of these stem cells, how to determine the best method of delivery, why ageing frailty is a condition that's particularly likely to respond positively to these types of stem cells, roadblocks to the development of research in this field, and what he thinks will happen over the next few years.
Tune in for the full conversation, and visit longeveron.com to learn more.
Transcript
Click on a timestamp to play from that location
| 0:00.0 | Welcome to Almost Here, Around the Corner of Future Technology Podcasts with Richard Jacobs. |
| 0:07.0 | Future Technologies is to transform our lives for better or worse or the focus of this podcast. |
| 0:13.0 | Almost here means these technologies are now here and starting to be used. |
| 0:17.0 | Or just around the corner, for Bitcoin to artificial intelligence, |
| 0:21.0 | 3D printing, blockchain, virtual reality, and more. |
| 0:25.0 | Hello this is Richard Jacobs with the Future Tech Podcast. My guest is Joshua Hare |
| 0:32.4 | MD. He's a co-founder and chief science officer at a company called |
| 0:36.6 | L-E-V-E-R-O-N-D-O-N. |
| 0:42.7 | So Josh, how you doing today? |
| 0:44.4 | Doing well, thank you for having me. |
| 0:46.3 | Yeah, we had discussed the work that lunch everyone was doing in aging. |
| 0:50.7 | So tell me the premise of the company first and then we'll go from there. |
| 0:54.0 | The company was founded four years ago with technology licensed from the University of Miami |
| 1:01.0 | Interdisciplinary Stem Cell Institute. |
| 1:04.0 | The premise is that aging is a major societal problem |
| 1:09.0 | that we're turning our attention to |
| 1:11.1 | in the biotechnology industry as something that's a |
| 1:14.8 | treatable condition and something that we can modify biologically to |
| 1:19.3 | improve the health span of people in our country and worldwide. |
| 1:24.7 | And the basic idea, the work that was formed the basis for the hypothesis that the company's |
| 1:31.8 | testing is that we could use |
| 1:33.2 | infusions of allogenic mesenchimal stem cells to treat people with a |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Richard Jacobs, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Richard Jacobs and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.